Abbott Laboratories (ABT) is back in focus after second quarter 2026 earnings topped market expectations, powered by Medical Devices and Diagnostics, and a higher full year adjusted EPS outlook lifted the stock sharply.

The latest results have triggered a sharp 1 day share price return of 10.71% and lifted Abbott Laboratories to US$98.83, yet the year to date share price return is still down 20.42% and the 1 year total shareholder return is down 16.09%. As a result, the current bounce comes against a weaker multi year track record.

If earnings driven moves like Abbott Laboratories' jump have your attention, this could be a good time to see what else is setting up for a rerating with the 39 healthcare AI stocks

After a double digit jump and a higher earnings outlook, the question with Abbott Laboratories is whether this reset already reflects the good news or whether a meaningful part of the rerating case still sits in front of the stock.

Most Popular Narrative: 15.2% Undervalued

With Abbott Laboratories closing at $98.83 against a widely followed fair value estimate of $116.54, the current reset sits below where the core narrative places the stock, and that gap is grounded in specific growth and margin forecasts rather than sentiment alone.

The global demographic shift toward an aging population and increasing prevalence of chronic and lifestyle-related diseases (e.g., diabetes, cardiovascular disease) is underpinning strong, recurring demand for Abbott's diagnostics, nutrition (e.g., Ensure, Glucerna), and high-growth medical device franchises, which in turn is supporting revenue acceleration and enhanced operating leverage.

Want to see what is behind that earnings and margin story for Abbott Laboratories? The narrative leans on steady top line expansion, firmer profitability, and a richer earnings multiple than today. Curious which specific growth and margin paths need to line up for that fair value to hold?

Result: Fair Value of $116.54 (UNDERVALUED)

However, this Abbott Laboratories narrative still depends on volume based procurement pressures in China easing, and on continuous glucose monitor pricing holding up against growing competition.

Next Steps

If this mix of optimism and concern around Abbott Laboratories has you thinking, move quickly to review the full picture and weigh both sides in detail using the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Abbott Laboratories?

If Abbott Laboratories has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to line up more opportunities that fit your style.

• Target dependable income by reviewing companies that qualify as 8 dividend fortresses
• Hunt for potential value by scanning stocks screened as screener containing 20 high quality undiscovered gems
• Prioritise resilience by concentrating on companies highlighted in the 82 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.